88 related articles for article (PubMed ID: 20227160)
1. Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome.
de la Torre J; Sabadell MD; Rojo F; Lirola JL; Salicru S; Reventos J; Ramón y Cajal S; Xercavins J
Eur J Obstet Gynecol Reprod Biol; 2010 Jul; 151(1):72-6. PubMed ID: 20227160
[TBL] [Abstract][Full Text] [Related]
2. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Oliveira VM; Piato S; Silva MA
Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
[TBL] [Abstract][Full Text] [Related]
3. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
Leo C; Faber S; Hentschel B; Höckel M; Horn LC
Ann Diagn Pathol; 2006 Dec; 10(6):327-32. PubMed ID: 17126249
[TBL] [Abstract][Full Text] [Related]
4. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
[TBL] [Abstract][Full Text] [Related]
5. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
[TBL] [Abstract][Full Text] [Related]
6. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
9. E2F-1: a proliferative marker of breast neoplasia.
Zhang SY; Liu SC; Al-Saleem LF; Holloran D; Babb J; Guo X; Klein-Szanto AJ
Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):395-401. PubMed ID: 10794484
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
Ranger GS; Jewell A; Thomas V; Mokbel K
J Surg Oncol; 2004 Nov; 88(2):100-3. PubMed ID: 15499599
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
12. Microinvasive (T1mic) lobular carcinoma of the breast: clinicopathologic profile of 16 cases.
Ross DS; Hoda SA
Am J Surg Pathol; 2011 May; 35(5):750-6. PubMed ID: 21415700
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast].
Zhou L; Wang Y; Song X; Du JW; Pei F; Huang LP; Wang WY; Liu ZB; Pan RQ
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3035-8. PubMed ID: 16324401
[TBL] [Abstract][Full Text] [Related]
14. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
15. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
16. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
[TBL] [Abstract][Full Text] [Related]
17. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
[TBL] [Abstract][Full Text] [Related]
18. Significance of HER2 protein examination in ductal carcinoma in situ.
Horimoto Y; Tokuda E; Arakawa A; Kosaka T; Saito M; Kasumi F
J Surg Res; 2011 May; 167(2):e205-10. PubMed ID: 20018297
[TBL] [Abstract][Full Text] [Related]
19. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas.
de Mascarel I; MacGrogan G; Mathoulin-Pélissier S; Soubeyran I; Picot V; Coindre JM
Cancer; 2002 Apr; 94(8):2134-42. PubMed ID: 12001109
[TBL] [Abstract][Full Text] [Related]
20. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
